ZJJF's wholly-owned subsidiary has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, ZJJF announced that recently, the company's wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") received the drug registration certificate for Rosadustat Capsules approved and issued by the National Medical Products Administration [Certificate No.: 2025S00631 (20mg); 2025S00632 (50mg)]. Rosadustat Capsules are indicated for anemia caused by chronic kidney disease (CKD), including patients on dialysis and those not on dialysis
According to the Zhitong Finance APP, ZJJF (600668.SH) announced that recently, the company's wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") received the drug registration certificate for Rosasita Capsules approved and issued by the National Medical Products Administration [Certificate No.: 2025S00631 (20mg); 2025S00632 (50mg)]. Rosasita Capsules are indicated for anemia caused by chronic kidney disease (CKD), including dialysis and non-dialysis patients